Ann: US patent to 2034 granted for Neuren's NNZ-2591 in autism, page-17

Not enough volume to concern me that is a dump. The SP will do what ever it does in the lead up to the P3 results- you could argue dumping, accumulation or capping. We are only 9 days away from seeing if the FDA have any issues to raise in relation to the Phelan-McDermid IND application, and another 9 days after that the same for the Pitt Hopkins IND application. Both these indications fall under the Neurology division of the FDA so we may have no issues. Angelman is under the Psychiatry division which is totally seperate.